Assessing the Impact of Rilonacept on Lipid Profiles in Patients With Recurrent Pericarditis.
作者信息
Bayat Aqieda, Agrawal Ankit, Kumar Ashwin, Majid Muhammad, Verma Beni, Yesilyaprak Abdullah, Klein Allan L
机构信息
Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
出版信息
JACC Adv. 2024 Dec 14;4(1):101437. doi: 10.1016/j.jacadv.2024.101437. eCollection 2025 Jan.
Abstract
摘要
相似文献
1
Assessing the Impact of Rilonacept on Lipid Profiles in Patients With Recurrent Pericarditis.评估利纳西普对复发性心包炎患者血脂谱的影响。
JACC Adv. 2024 Dec 14;4(1):101437. doi: 10.1016/j.jacadv.2024.101437. eCollection 2025 Jan.
2
What is rilonacept's role in treating recurrent pericarditis?利那洛肽在治疗复发性心包炎中的作用是什么？
JAAPA. 2022 Nov 1;35(11):18-19. doi: 10.1097/01.JAA.0000889900.27212.8d.
3
Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY.白细胞介素-1 陷阱利纳西普在复发性心包炎患者中改善健康相关生活质量和睡眠：来自 3 期临床试验 RHAPSODY 的结果。
J Am Heart Assoc. 2022 Oct 18;11(20):e023252. doi: 10.1161/JAHA.121.023252. Epub 2022 Oct 17.
4
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.利那洛肽：一种新批准的复发性心包炎治疗方法。
Ann Pharmacother. 2022 May;56(5):572-581. doi: 10.1177/10600280211036499. Epub 2021 Aug 28.
5
Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis.利罗那肽和阿那白滞素治疗复发性心包炎的系统评价与荟萃分析
Cureus. 2022 Nov 8;14(11):e31226. doi: 10.7759/cureus.31226. eCollection 2022 Nov.
6
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.白细胞介素-1受体拮抗剂rilonacept治疗复发性心包炎的3期试验
N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16.
7
A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option.复发性心包炎治疗概述及利纳西普作为一种新的治疗选择的潜力。
Am J Cardiovasc Drugs. 2022 Jan;22(1):27-33. doi: 10.1007/s40256-021-00481-x. Epub 2021 May 19.
8
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.从口服药物转换为利那洛肽单药治疗复发性心包炎患者。
Heart. 2023 Jan 27;109(4):297-304. doi: 10.1136/heartjnl-2022-321328.
9
Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis.利纳西普（白细胞介素-1 抑制剂）治疗心包炎。
Curr Cardiol Rep. 2022 Jan;24(1):23-30. doi: 10.1007/s11886-021-01621-0. Epub 2022 Jan 6.
10
The Role of Rilonacept in Recurrent Pericarditis.利洛纳塞在复发性心包炎中的作用
Heart Int. 2021 Jul 16;15(1):20-25. doi: 10.17925/HI.2021.15.1.20. eCollection 2021.
引用本文的文献
1
Endothelial dysfunction in chronic kidney disease: a clinical perspective.慢性肾脏病中的内皮功能障碍：临床视角
Am J Physiol Heart Circ Physiol. 2025 Jul 1;329(1):H135-H153. doi: 10.1152/ajpheart.00908.2024. Epub 2025 May 27.
本文引用的文献
1
Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging.心包疾病：多模态心脏成像新概念和新进展的国际立场声明。
JACC Cardiovasc Imaging. 2024 Aug;17(8):937-988. doi: 10.1016/j.jcmg.2024.04.010.
2
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.白细胞介素-1受体拮抗剂rilonacept治疗复发性心包炎的3期试验
N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16.
3
2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).2015年欧洲心脏病学会（ESC）心包疾病诊断和管理指南：欧洲心脏病学会（ESC）心包疾病诊断和管理工作组 认可机构：欧洲心胸外科学会（EACTS）
Eur Heart J. 2015 Nov 7;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29.
Zotero 插件